306 related articles for article (PubMed ID: 33969633)
1. Oncohistones: a roadmap to stalled development.
Deshmukh S; Ptack A; Krug B; Jabado N
FEBS J; 2022 Mar; 289(5):1315-1328. PubMed ID: 33969633
[TBL] [Abstract][Full Text] [Related]
2. Oncohistones: drivers of pediatric cancers.
Mohammad F; Helin K
Genes Dev; 2017 Dec; 31(23-24):2313-2324. PubMed ID: 29352018
[TBL] [Abstract][Full Text] [Related]
3. Depletion of H3K36me2 recapitulates epigenomic and phenotypic changes induced by the H3.3K36M oncohistone mutation.
Rajagopalan KN; Chen X; Weinberg DN; Chen H; Majewski J; Allis CD; Lu C
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33619101
[TBL] [Abstract][Full Text] [Related]
4. Histone deposition pathways determine the chromatin landscapes of H3.1 and H3.3 K27M oncohistones.
Sarthy JF; Meers MP; Janssens DH; Henikoff JG; Feldman H; Paddison PJ; Lockwood CM; Vitanza NA; Olson JM; Ahmad K; Henikoff S
Elife; 2020 Sep; 9():. PubMed ID: 32902381
[TBL] [Abstract][Full Text] [Related]
5. Cancer cell metabolism connects epigenetic modifications to transcriptional regulation.
Morrison AJ
FEBS J; 2022 Mar; 289(5):1302-1314. PubMed ID: 34036737
[TBL] [Abstract][Full Text] [Related]
6. The dark side of histones: genomic organization and role of oncohistones in cancer.
Amatori S; Tavolaro S; Gambardella S; Fanelli M
Clin Epigenetics; 2021 Apr; 13(1):71. PubMed ID: 33827674
[TBL] [Abstract][Full Text] [Related]
7. Epigenetics in cancer: targeting chromatin modifications.
Ellis L; Atadja PW; Johnstone RW
Mol Cancer Ther; 2009 Jun; 8(6):1409-20. PubMed ID: 19509247
[TBL] [Abstract][Full Text] [Related]
8. Histone H3K27M Mutation in Brain Tumors.
El-Hashash AHK
Adv Exp Med Biol; 2021; 1283():43-52. PubMed ID: 33155136
[TBL] [Abstract][Full Text] [Related]
9. Histone isoforms and the oncohistone code.
Flaus A; Downs JA; Owen-Hughes T
Curr Opin Genet Dev; 2021 Apr; 67():61-66. PubMed ID: 33285512
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of cancer: Oncohistones in action.
Qiu L; Hu X; Jing Q; Zeng X; Chan KM; Han J
J Genet Genomics; 2018 May; 45(5):227-236. PubMed ID: 29804713
[TBL] [Abstract][Full Text] [Related]
11. Rebelled epigenome: histone H3S10 phosphorylation and H3S10 kinases in cancer biology and therapy.
Komar D; Juszczynski P
Clin Epigenetics; 2020 Oct; 12(1):147. PubMed ID: 33054831
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of chromatin: status and opportunities.
Siklos M; Kubicek S
FEBS J; 2022 Mar; 289(5):1276-1301. PubMed ID: 33982887
[TBL] [Abstract][Full Text] [Related]
13. Oncohistones in brain tumors: the soil and seed.
Andrade AF; Chen CCL; Jabado N
Trends Cancer; 2023 May; 9(5):444-455. PubMed ID: 36933956
[TBL] [Abstract][Full Text] [Related]
14. Histone mutations in cancer.
Espinoza Pereira KN; Shan J; Licht JD; Bennett RL
Biochem Soc Trans; 2023 Oct; 51(5):1749-1763. PubMed ID: 37721138
[TBL] [Abstract][Full Text] [Related]
15. Cancer epigenetics: promises and pitfalls for cancer therapy.
Skourti E; Dhillon P
FEBS J; 2022 Mar; 289(5):1156-1159. PubMed ID: 35233949
[TBL] [Abstract][Full Text] [Related]
16. The expanding landscape of 'oncohistone' mutations in human cancers.
Nacev BA; Feng L; Bagert JD; Lemiesz AE; Gao J; Soshnev AA; Kundra R; Schultz N; Muir TW; Allis CD
Nature; 2019 Mar; 567(7749):473-478. PubMed ID: 30894748
[TBL] [Abstract][Full Text] [Related]
17. Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression.
Jain SU; Khazaei S; Marchione DM; Lundgren SM; Wang X; Weinberg DN; Deshmukh S; Juretic N; Lu C; Allis CD; Garcia BA; Jabado N; Lewis PW
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27354-27364. PubMed ID: 33067396
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets.
Herranz M; Esteller M
Methods Mol Biol; 2007; 361():25-62. PubMed ID: 17172706
[TBL] [Abstract][Full Text] [Related]
19. Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis.
Chen CCL; Deshmukh S; Jessa S; Hadjadj D; Lisi V; Andrade AF; Faury D; Jawhar W; Dali R; Suzuki H; Pathania M; A D; Dubois F; Woodward E; Hébert S; Coutelier M; Karamchandani J; Albrecht S; Brandner S; De Jay N; Gayden T; Bajic A; Harutyunyan AS; Marchione DM; Mikael LG; Juretic N; Zeinieh M; Russo C; Maestro N; Bassenden AV; Hauser P; Virga J; Bognar L; Klekner A; Zapotocky M; Vicha A; Krskova L; Vanova K; Zamecnik J; Sumerauer D; Ekert PG; Ziegler DS; Ellezam B; Filbin MG; Blanchette M; Hansford JR; Khuong-Quang DA; Berghuis AM; Weil AG; Garcia BA; Garzia L; Mack SC; Beroukhim R; Ligon KL; Taylor MD; Bandopadhayay P; Kramm C; Pfister SM; Korshunov A; Sturm D; Jones DTW; Salomoni P; Kleinman CL; Jabado N
Cell; 2020 Dec; 183(6):1617-1633.e22. PubMed ID: 33259802
[TBL] [Abstract][Full Text] [Related]
20. Targeting Histone Methylation in Cancer.
McCabe MT; Mohammad HP; Barbash O; Kruger RG
Cancer J; 2017; 23(5):292-301. PubMed ID: 28926430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
